The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Kidney Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Kidney Diseases


Psychiatry related information on Kidney Diseases

  • There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml [6].

High impact information on Kidney Diseases

  • A new TRP to kidney disease [7].
  • Phenacetin abuse is known to produce kidney disease; salicylate use is supposed to prevent cardiovascular disease [8].
  • The urinary excretion of N-acetyl-beta-glucosaminidase (NAG) is increased in patients whose renal function is impaired by a variety of kidney diseases, and may provide an index of renal injury [9].
  • Mutations in the homeobox gene vHnf1 are associated with human diseases MODY5 (maturity-onset diabetes of the young, type V) and familial GCKD (glomerulocystic kidney disease) [10].
  • JAMA patient page. Hypertensive kidney disease [11].

Chemical compound and disease context of Kidney Diseases


Biological context of Kidney Diseases


Anatomical context of Kidney Diseases


Gene context of Kidney Diseases


Analytical, diagnostic and therapeutic context of Kidney Diseases


  1. A gene for familial juvenile nephronophthisis (recessive medullary cystic kidney disease) maps to chromosome 2p. Antignac, C., Arduy, C.H., Beckmann, J.S., Benessy, F., Gros, F., Medhioub, M., Hildebrandt, F., Dufier, J.L., Kleinknecht, C., Broyer, M. Nat. Genet. (1993) [Pubmed]
  2. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Border, W.A., Noble, N.A., Yamamoto, T., Harper, J.R., Yamaguchi, Y., Pierschbacher, M.D., Ruoslahti, E. Nature (1992) [Pubmed]
  3. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. Burlingame, R.W., Boey, M.L., Starkebaum, G., Rubin, R.L. J. Clin. Invest. (1994) [Pubmed]
  4. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)-fluoromethylketone. Seery, J.P., Cattell, V., Watt, F.M. J. Immunol. (2001) [Pubmed]
  5. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Hou, C.C., Wang, W., Huang, X.R., Fu, P., Chen, T.H., Sheikh-Hamad, D., Lan, H.Y. Am. J. Pathol. (2005) [Pubmed]
  6. Age and renal clearance of cimetidine. Drayer, D.E., Romankiewicz, J., Lorenzo, B., Reidenberg, M.M. Clin. Pharmacol. Ther. (1982) [Pubmed]
  7. A new TRP to kidney disease. Gudermann, T. Nat. Genet. (2005) [Pubmed]
  8. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). Dubach, U.C., Rosner, B., Stürmer, T. N. Engl. J. Med. (1991) [Pubmed]
  9. Increased excretion of urinary N-acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. Alderman, M.H., Melcher, L., Drayer, D.E., Reidenberg, M.M. N. Engl. J. Med. (1983) [Pubmed]
  10. vhnf1, the MODY5 and familial GCKD-associated gene, regulates regional specification of the zebrafish gut, pronephros, and hindbrain. Sun, Z., Hopkins, N. Genes Dev. (2001) [Pubmed]
  11. JAMA patient page. Hypertensive kidney disease. Torpy, J., Lynm, C., Glass, R.M. JAMA (2002) [Pubmed]
  12. An evaluation of iridology. Simon, A., Worthen, D.M., Mitas, J.A. JAMA (1979) [Pubmed]
  13. Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. Volpi, E., Sheffield-Moore, M., Rasmussen, B.B., Wolfe, R.R. JAMA (2001) [Pubmed]
  14. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Ketteler, M., Noble, N.A., Border, W.A. Annu. Rev. Physiol. (1995) [Pubmed]
  15. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Purkerson, M.L., Joist, J.H., Yates, J., Valdes, A., Morrison, A., Klahr, S. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  16. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Yu, C.C., Yen, T.S., Lowell, C.A., DeFranco, A.L. Curr. Biol. (2001) [Pubmed]
  17. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. Jevnikar, A.M., Grusby, M.J., Glimcher, L.H. J. Exp. Med. (1994) [Pubmed]
  18. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Lu, C., He, J.C., Cai, W., Liu, H., Zhu, L., Vlassara, H. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  19. Polycystic kidney disease as a result of loss of the tuberous sclerosis 2 tumor suppressor gene during development. Cai, S., Everitt, J.I., Kugo, H., Cook, J., Kleymenova, E., Walker, C.L. Am. J. Pathol. (2003) [Pubmed]
  20. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. Becker, B., Kronenberg, F., Kielstein, J.T., Haller, H., Morath, C., Ritz, E., Fliser, D. J. Am. Soc. Nephrol. (2005) [Pubmed]
  21. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. Zoja, C., Perico, N., Corna, D., Benigni, A., Gabanelli, M., Morigi, M., Bertani, T., Remuzzi, G. J. Am. Soc. Nephrol. (1990) [Pubmed]
  22. Differential expression of collagen IV isoforms in experimental glomerulosclerosis. Bergijk, E.C., Van Alderwegen, I.E., Baelde, H.J., de Heer, E., Funabiki, K., Miyai, H., Killen, P.D., Kalluri, R.K., Bruijn, J.A. J. Pathol. (1998) [Pubmed]
  23. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. Papavasiliou, E.C., Gouva, C., Siamopoulos, K.C., Tselepis, A.D. Kidney Int. (2005) [Pubmed]
  24. Retinoids in nephrology: promises and pitfalls. Xu, Q., Lucio-Cazana, J., Kitamura, M., Ruan, X., Fine, L.G., Norman, J.T. Kidney Int. (2004) [Pubmed]
  25. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Anders, H.J., Ninichuk, V., Schlöndorff, D. Kidney Int. (2006) [Pubmed]
  26. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Isbel, N.M., Hill, P.A., Foti, R., Mu, W., Hurst, L.A., Stambe, C., Lan, H.Y., Atkins, R.C., Nikolic-Paterson, D.J. Kidney Int. (2001) [Pubmed]
  27. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Li, X., Luo, Y., Starremans, P.G., McNamara, C.A., Pei, Y., Zhou, J. Nat. Cell Biol. (2005) [Pubmed]
  28. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Egle, A., Harris, A.W., Bath, M.L., O'Reilly, L., Cory, S. Blood (2004) [Pubmed]
  29. Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus. Yang, Y., Lhotta, K., Chung, E.K., Eder, P., Neumair, F., Yu, C.Y. J. Immunol. (2004) [Pubmed]
  30. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. Jacob, C.O., Zang, S., Li, L., Ciobanu, V., Quismorio, F., Mizutani, A., Satoh, M., Koss, M. J. Immunol. (2003) [Pubmed]
  31. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Bennett, C.L., Cournoyer, D., Carson, K.R., Rossert, J., Luminari, S., Evens, A.M., Locatelli, F., Belknap, S.M., McKoy, J.M., Lyons, E.A., Kim, B., Sharma, R., Costello, S., Toffelmire, E.B., Wells, G.A., Messner, H.A., Yarnold, P.R., Trifilio, S.M., Raisch, D.W., Kuzel, T.M., Nissenson, A., Lim, L.C., Tallman, M.S., Casadevall, N. Blood (2005) [Pubmed]
  32. Pax-2 controls multiple steps of urogenital development. Torres, M., Gómez-Pardo, E., Dressler, G.R., Gruss, P. Development (1995) [Pubmed]
  33. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. Boes, E., Fliser, D., Ritz, E., König, P., Lhotta, K., Mann, J.F., Müller, G.A., Neyer, U., Riegel, W., Riegler, P., Kronenberg, F. J. Am. Soc. Nephrol. (2006) [Pubmed]
  34. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. Wong, T.Y., Coresh, J., Klein, R., Muntner, P., Couper, D.J., Sharrett, A.R., Klein, B.E., Heiss, G., Hubbard, L.D., Duncan, B.B. J. Am. Soc. Nephrol. (2004) [Pubmed]
  35. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Allon, M., Kleinman, K., Walczyk, M., Kaupke, C., Messer-Mann, L., Olson, K., Heatherington, A.C., Maroni, B.J. Clin. Pharmacol. Ther. (2002) [Pubmed]
WikiGenes - Universities